Turning Point Therapeutics, Inc. Stock, NASDAQ:TPTX
10628 Science Center Drive, Suite 200, San Diego, California 92121
United States of America
Number of Employees: 95
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.